Hikma Shares Surge 10% on H1 Profit Beat

Key Facts

In a move reflecting the resilience of the healthcare sector amid economic shifts, Hikma Pharmaceuticals shares saw a significant rally. The company's stock jumped 10% to reach 1,721p following the announcement of strong first-half 2026 financial results that exceeded market expectations. According to reports, the surge was triggered by a substantial profit beat, leading analysts at Peel Hunt and Stifel to maintain their 'buy' recommendations for the stock.

Financial data showed that the Branded division's revenue grew 15% to $502 million, while its operating profit rose 23%. The group's core operating profit reached $405 million, approximately 11% above the $364 million analyst consensus. Despite this strong performance, Hikma left its full-year guidance unchanged, targeting revenue growth of 2% to 4% and core operating profit between $720 million and $770 million.

Technically, the share price is approaching Stifel's target of 1,700p, while Peel Hunt maintains a higher target of 1,880p. Traders in the UK market are also keeping an eye on broader monetary policy impacts, following the recent decision to hold interest rates at 3.75% at the end of July.